Taletrectinib is currently being evaluated in multiple Phase 2 clinical trials in first and second-line ROS1-positive NSCLC. The global Phase 2 trial TRUST-II is actively enrolling patients. The China Phase 2 trial TRUST has enrolled more than 100 patients. Two Phase 1 trials, one conducted in the US and the other study in Japan, have been successfully completed.
Taletrectinib for ROS1 fusion-positive NSCLC
| Trial Title | Trial Number | Stage | Status | Publication |
|---|---|---|---|---|
|
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC (TRUST-II) |
Phase 2, Global (US, Japan, Korea, Europe, Canada, and China ) |
Recruiting |
ASCO 2022 Trial in Progress | |
|
A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene (TRUST) |
Phase 2, China |
Recruiting |
ASCO 2022 Efficacy and Safety Result Updates, as of Feb 23, 2022 | |
|
Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors |
Phase 1, Japan |
Completed |
JTO 2021, pooled analysis of the two Phase 1 studies CCR 2020, US phase 1 study Oncotarget 2018, Japan phase 1 study |
|
|
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b |
Phase 1, US |
Completed |
JTO 2021, pooled analysis of the two Phase 1 studies CCR 2020, US phase 1 study Oncotarget 2018, Japan phase 1 study |
Contact Us
For questions about ongoing clinical trials, please contact trials@anhearttherapeutics.com.
“Taletrectinib (AB106/DS6051b) has shown meaningful clinical activity in patients with advanced ROS1+ NSCLC who are ROS1 TKI-naive or crizotinib-refractory and a manageable safety profile.”
from Jan 2021, JTO Clinical and Research Reports.
